EMAIL DETAILS

So in preparation for Counsyl going public, they will need to beef up their
story to be big and have important societal impact, and have proof in terms
of R&D, initiates, etc. that are resourced and up and running supporting
that big story.


And the envisioned value prop is they are a platform that is wide but not
deep and can be the industry platform for other genomics companies that want
to be narrow and deep on a particular content area (i.e., ocular, bone,
cardio, etc.).


Maybe we bring the concept to Counsyl, maybe with some other folks (NIH?) as
a project/initiative that we can help seed/lead. We could write that up,
come it with a draft concept.


For the Counsyl closing dinner on the 21st - I am going to go solo (there is
nobody on the planet that could take care of my four kids for a few days
without me or Maria at this point J). I am coming back on the redeye at
11:30pm that night, so it will be a quick dinner, but I get home by 9am
Saturday.


Maybe we go and meet Counsyl at their offices on Thursday the 20th - and we
could share the project idea and see what we can get going? I think "going
direct" to Counsyl would be the approach that would be most impactful.


And there is something to us having a "med-tech" focus - with Counsyl,
Medabiota, your role at WFP, Care, One, relationship with StartUp Health -
we could be a very credible med-tech platform and raise a $1B to pursue -
much bigger and longer term and important than consumer internet stuff!


Neil Callahan

152 West 57th, 47th Floor

New York, NY 10019

212-933-9965 (o)

917-945-9516 (m)

866-749-8879 (f)

www.rstp.com <http://www.rstp.com/>


Confidentiality Warning: This e-mail contains information intended only for
the use of the individual or entity named above. If the reader of this
e-mail is not the intended recipient or the employee or agent responsible
for delivering it to the intended recipient, any dissemination, publication
or copying of this e-mail is strictly prohibited. The sender does not accept
any responsibility for any loss, disruption or damage to your data or
computer system that may occur while using data contained in, or transmitted
with, this e-mail.If you have received this e-mail in error, please
immediately notify us by return e-mail. Thank you


From: Hunter Biden [mailto:hbiden@rosemontseneca.com]
Sent: Wednesday, March 05, 2014 9:57 AM
To: Neil Callahan
Cc: Devon Archer
Subject: Re: NYTimes: A Powerful New Way to Edit DNA


I was thinking the same thing regarding Counsyl. I don't know enough to
know what Counsyl has the ability to do, but it certainly seems like they
would have a jump on identifying the first genetic disorders that could
benefit from Crispr genomic manipulation. And yes you are right regarding
cancer- the holy grail is finding the key to halting the cancer cells
unfettered mutation in the body. Current therapies all (except for melanoma
now) employ the shotgun (radiation/ chemo) approach. The treatment is more
often the cause of death than the cancer itself. Anyway, I just find it
fascinating on so many levels and believe that it is truly the next
frontier. Did you read the Sunday Times Magazine article on bringing
extinct species back to life ala Jurassic Park. It's no longer science
fiction it is real and it's doable now at a relatively reasonable cost. I
truly believe that the collision of the exponential advances in computing
power and the understanding of the human genome will radically alter the way
we live within our lifetimes.

R. Hunter Biden

Rosemont Seneca Partners

Washington D.C.

202-333-1880


On Mar 5, 2014, at 9:36 AM, Neil Callahan <ncallahan@rosemontseneca.com>
wrote:


Science fiction coming true - going to the doctor for a cure will be some
odd cone head in a cape doing some magnetic injections and in a few days you
are fine.

Huge impact to health care for chronic conditions - maybe they all get
cured? I bet stopping cancer cells from replicating is a huge focus of
this technology, especially for pancreatic which is untreatable at this
point.

Could be the next Pharma - an R&D IP play, huge capital infusion, develop
techniques and then license a them for clinical uses. And then protecting
and marketing the IP to get the ROI on the R&D.

Family Offices really like exposure to these type of opportunities - patient
capital long term looking, but big societal impact (all of Howard Hughes
fortune is in a foundation only investing in health/life science
innovation). Also Goldman can take this to their clients as they've done
with Counsyl.

Should Counsyl start an effort to extend their platform to be a tool for
this field of genomics? Could start as a thought leadership / prototype
effort and then evolve to their next product or platform extension.

--------------------
Neil Callahan
Rosemont Seneca
917-945-9516


On Mar 5, 2014, at 8:17 AM, Hunter Biden <hbiden@rosemontseneca.com> wrote:

Genome engineering will not only fundamentally change the way we live- it
will change the way we think about life and death. It's amazing.

RHB
202.333.1880


On Mar 5, 2014, at 12:19 AM, Neil Callahan <ncallahan@rosemontseneca.com>
wrote:

Facinating. Huge potential impact on the health care paradigm and the food
supply paradigm.

--------------------
Neil Callahan
Rosemont Seneca
917-945-9516


On Mar 4, 2014, at 9:33 PM, Hunter Biden <hbiden@rosemontseneca.com> wrote:

http://nyti.ms/1fCYbTG

A technique is stirring excitement while raising profound questions.


RHB
202.333.1880